S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:MRTX

Mirati Therapeutics (MRTX) Stock Forecast, Price & News

$38.26
+1.25 (+3.38%)
(As of 06/2/2023 ET)
Compare
Today's Range
$36.85
$38.40
50-Day Range
$36.54
$49.49
52-Week Range
$35.70
$101.30
Volume
1.13 million shs
Average Volume
1.02 million shs
Market Capitalization
$2.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$76.93

Mirati Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
101.1% Upside
$76.93 Price Target
Short Interest
Healthy
11.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
0.06mentions of Mirati Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$200,252 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($12.55) to ($10.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

355th out of 983 stocks

Pharmaceutical Preparations Industry

165th out of 486 stocks


MRTX stock logo

About Mirati Therapeutics (NASDAQ:MRTX) Stock

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Stock News Headlines

"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Barclays Remains a Buy on Mirati Therapeutics (MRTX)
Analyst Expectations for Mirati Therapeutics's Future
Mirati Therapeutics (MRTX) Receives a Buy from JMP Securities
See More Headlines

MRTX Price History

MRTX Company Calendar

Last Earnings
5/09/2023
Today
6/04/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
413
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$76.93
High Stock Price Forecast
$188.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+101.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-740,870,000.00
Net Margins
-3,901.06%
Pretax Margin
-3,898.38%

Debt

Sales & Book Value

Annual Sales
$18.89 million
Book Value
$14.82 per share

Miscellaneous

Free Float
56,168,000
Market Cap
$2.23 billion
Optionable
Optionable
Beta
1.02

Social Links


Key Executives

  • David D. Meek
    Chief Executive Officer & Director
  • Charles M. BaumCharles M. Baum
    President, Director & Head-Research & Development
  • Laurie D. Stelzer
    Chief Financial Officer
  • James G. ChristensenJames G. Christensen
    Chief Scientific Officer
  • Alan Bart Sandler
    Chief Medical Officer & Executive Vice President













MRTX Stock - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRTX shares.
View MRTX analyst ratings
or view top-rated stocks.

What is Mirati Therapeutics' stock price forecast for 2023?

12 Wall Street research analysts have issued 12-month price targets for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $40.00 to $188.00. On average, they predict the company's share price to reach $76.93 in the next year. This suggests a possible upside of 101.1% from the stock's current price.
View analysts price targets for MRTX
or view top-rated stocks among Wall Street analysts.

How have MRTX shares performed in 2023?

Mirati Therapeutics' stock was trading at $45.31 at the start of the year. Since then, MRTX shares have decreased by 15.6% and is now trading at $38.26.
View the best growth stocks for 2023 here
.

Are investors shorting Mirati Therapeutics?

Mirati Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 6,760,000 shares, a decrease of 14.8% from the April 30th total of 7,930,000 shares. Based on an average daily trading volume, of 981,200 shares, the short-interest ratio is presently 6.9 days.
View Mirati Therapeutics' Short Interest
.

When is Mirati Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our MRTX earnings forecast
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) posted its quarterly earnings results on Tuesday, May, 9th. The biotechnology company reported ($3.18) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.29. The biotechnology company earned $7.17 million during the quarter, compared to the consensus estimate of $4.80 million. Mirati Therapeutics had a negative net margin of 3,901.06% and a negative trailing twelve-month return on equity of 71.90%. Mirati Therapeutics's revenue was up 910.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.40) EPS.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (6.35%), BlackRock Inc. (5.57%), Wellington Management Group LLP (4.64%), State Street Corp (3.97%), Price T Rowe Associates Inc. MD (3.04%) and Perceptive Advisors LLC (2.71%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Henry J Fuchs, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Laurie Stelzer, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends
.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $38.26.

How much money does Mirati Therapeutics make?

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.23 billion and generates $18.89 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($12.96) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

The company employs 413 workers across the globe.

Does Mirati Therapeutics have any subsidiaries?
The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..
Read More
How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.

This page (NASDAQ:MRTX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -